20:22:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 15-10 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2024-05-07 10:35:00

INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") announced on 16 March 2024 an update on the Company's financial situation and current operations as well as the intention to apply for a delisting of 2cureX shares from Nasdaq First North Growth Market in Stockholm. The Board of Directors of 2cureX has resolved to proceed with a formal delisting application. In accordance with good market practise on the Swedish stock market, 2cureX will after three months from the announcement on 16 March 2024 file an official request for delisting to Nasdaq Stockholm AB, which will be made on 17 June 2024. The last day of trading in 2cureX shares is expected to be on 28 June 2024.

Background

2cureX was founded in 2007 and listed at Nasdaq First North Growth Market in 2017. 2cureX has during this period developed, clinically validated and CE IVD certified its 3D functional drug sensitivity test, IndiTreat. However, 2cureX has over the last two years experienced a significant decline in the Company's share price which has significantly affected the possibilities to raise capital. The negative trend has primarily been caused by a failed business strategy (for details see Interim Report Q4 2023).
Decision to delist the Company's shares on Nasdaq First North Growth Market and Outlook
As a result of the significant decline in the Company's share price the last two years and the current operational status of the Company, the liquidity and trading in the share on Nasdaq First North Growth Market has also significantly decreased. Qualified shareholders[1] in the Company's shares are significantly below the initial listing requirement of 300 qualified shareholders. It has also been concluded that the Company does not meet several of the applicable ongoing listing requirements on Nasdaq First North Growth Market. Furthermore, the Company is still in a severely financial distressed position as announced on 16 March 2024. The Board of Directors believes that the best way of securing future financing and growth of the company will be as an unlisted private company. Therefore, it has decided to apply for a delisting of the Company's shares on Nasdaq First North Growth Market in Stockholm.

The Company is confident that it, as private company, will be able to execute on its revised business plan to develop IndiTreat® as a decentralized offering for individual hospitals.

Delisting procedure and timeline

In accordance with good practice on the Swedish stock market an application for delisting may at the earliest be filed three months after the announcement on 16 March 2024, which is 17 June 2024. Delisting the Company's shares from trading on Nasdaq First North Growth Market in Stockholm is conditional on the request being approved by Nasdaq Stockholm AB. The Company's shares will continue to be tradable until the last day of trading. The last day of trading is determined by Nasdaq Stockholm AB and is expected to be on 28 June 2024. Following the last day of trading, the Company's share will be removed from trading on Nasdaq First North Growth Market. The Company will publicly announce the submission of the delisting application and subsequently upon receiving Nasdaq Stockholm AB's approval of the delisting and the last day of trading.

There will be no obligation for the Company’s shareholders to sell their shares in connection with the delisting process.

Effects on the Company's shareholders

As a result of delisting the Company's shares on Nasdaq First North Growth Market, there will effectively no longer be an active marketplace for trading of the Company's shares. Any future trades in the Company's shares will be "over-the-counter". For this reason, the liquidity of the Company's shares will decrease further. This will also mean that it becomes more difficult to execute transactions in the Company's shares which may require legal assistance. Parties involved in over-the-counter transactions must finance any needed legal assistance themselves. Furthermore, by delisting, the Company will no longer be covered by, among other things, the disclosure obligations of the Market Abuse Regulation (MAR) and the set of rules that apply to companies admitted to trading on Nasdaq First North Growth Market. However, the Company will continue to be covered by, among other things, the rules of the Swedish Companies Act and the Swedish Annual Accounts Act.

There may be changes in a shareholder's tax legal position in relation to the delisting of the shares and current shareholders might not be eligible to hold shares in a Swedish Investment Savings Account (Sw. Investeringssparkonto) after the delisting. Shareholders are encouraged to consult expertise in this regard.

[1] Shareholders holding shares with a value of at least EUR 500